Revealing Anisotropic Growth of Liraglutide Oligomers by Native Ion Mobility Mass Spectrometry and Molecular Dynamics Simulation.
ACS Cent Sci · 2025
Last updated 2026-08-28| Journal | ACS Cent Sci, 2025 |
|---|---|
| Citations | 3 |
| Molecules | liraglutide |
Abstract
Oligomerization is an intriguing problem, particularly at the early stages of soluble prefibril oligomer formation, where the growth mechanisms of these species remain difficult to study due to their complexity and heterogeneity. Liraglutide, a widely used drug for diabetes and obesity, has demonstrated various oligomerization outcomes in different studies. In this study, we integrate native ion mobility mass spectrometry (nIM-MS) and molecular dynamics (MD) simulations to unravel the assembly mechanisms of liraglutide oligomers. Our findings reveal that while assembly pathways vary in their steps, they consistently converge into a structure resembling a fuzzy oil drop model. Furthermore, a key residue is identified as a determining factor in oligomerization. The preference for specific shapes varies at different stages of oligomer formation depending on the oligomer size. A theoretical model is proposed to fit collisional cross-section (CCS) data and is verified through both nIM-MS experiments and MD simulations, ultimately establishing an anisotropic growth mechanism for liraglutide. Additional MD simulations provide deeper insights into monomer conformations, which are closely linked to oligomer formation. A bias toward forming extended monomers is shown to facilitate the assembly of larger oligomers in this self-assembling system.
Verbatim abstract via PubMed 40726781 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.